标题/作者	年份
Omicron and Delta variant of SARS‐CoV‐2: a comparative computational study of spike protein S Kumar, TS Thambiraja, K Karuppanan, G Subramaniam Journal of medical virology 94 (4), 1641-1649	2022
The Lancet Commission on lessons for the future from the COVID-19 pandemic JD Sachs, SSA Karim, L Aknin, J Allen, K Brosbøl, F Colombo, GC Barron, ... The Lancet 400 (10359), 1224-1280	2022
SARS-CoV-2 mutations and their impact on diagnostics, therapeutics and vaccines S Thakur, S Sasi, SG Pillai, A Nag, D Shukla, R Singhal, S Phalke, ... Frontiers in medicine 9, 815389	2022
Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease DW Kneller, H Li, G Phillips, KL Weiss, Q Zhang, MA Arnould, CB Jonsson, ... Nature communications 13 (1), 2268	2022
Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants J Yin, C Li, C Ye, Z Ruan, Y Liang, Y Li, J Wu, Z Luo Computational and structural biotechnology journal 20, 824-837	2022
Severity, pathogenicity and transmissibility of delta and lambda variants of SARS-CoV-2, toxicity of spike protein and possibilities for future prevention of COVID-19 M Moghaddar, R Radman, I Macreadie Microorganisms 9 (10), 2167	2021
Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here DT Halperin, N Hearst, S Hodgins, RC Bailey, JD Klausner, H Jackson, ... BMC public health 21 (1), 1-12	2021
Delta variant (B. 1.617. 2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions M Dhawan, A Sharma, n Priyanka, N Thakur, TK Rajkhowa, ... Human Vaccines & Immunotherapeutics 18 (5), 2068883	2022
A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies S Chatterjee, M Bhattacharya, S Nag, K Dhama, C Chakraborty Viruses 15 (1), 167	2023
SARS-CoV-2 omicron variant: Could it be another threat? B Shanmugaraj, A Malla, N Khorattanakulchai, W Phoolcharoen Journal of Medical Virology 94 (4), 1284-1288	2022
A multi-strain epidemic model for COVID-19 with infected and asymptomatic cases: Application to French data M Massard, R Eftimie, A Perasso, B Saussereau Journal of Theoretical Biology 545, 111117	2022
Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2 J Newman, N Thakur, TP Peacock, D Bialy, AME Elrefaey, C Bogaardt, ... Nature microbiology 7 (8), 1180-1188	2022
Identification of SARS-CoV-2 variants using viral sequencing for the Centers for Disease Control and Prevention genomic surveillance program C Goswami, M Sheldon, C Bixby, M Keddache, A Bogdanowicz, Y Wang, ... BMC Infectious Diseases 22 (1), 404	2022
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials M Eugenia-Toledo-Romaní, L Verdecia-Sánchez, M Rodríguez-González, ... Vaccine 40 (31), 4220-4230	2022
The Delta and Omicron variants of SARS-CoV-2: what we know so far VP Chavda, R Bezbaruah, K Deka, L Nongrang, T Kalita Vaccines 10 (11), 1926	2022
The importance of vaccination in the context of the COVID-19 pandemic: a brief update regarding the use of vaccines BAS Machado, KVS Hodel, LMS Fonseca, VC Pires, LAB Mascarenhas, ... Vaccines 10 (4), 591	2022
Interspecies jumping of bat coronaviruses ACP Wong, SKP Lau, PCY Woo Viruses 13 (11), 2188	2021
Real-world effectiveness of mix-and-match vaccine regimens against SARS-CoV-2 Delta variant in Thailand: a nationwide test-negative matched case-control study R Suphanchaimat, N Nittayasoot, C Jiraphongsa, P Thammawijaya, ... Vaccines 10 (7), 1080	2022
Omicron (B. 1.1. 529)-a new heavily mutated variant: mapped location and probable properties of its mutations with an emphasis on S-glycoprotein C Chakraborty, M Bhattacharya, AR Sharma, B Mallik International Journal of Biological Macromolecules 219, 980-997	2022
Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivity BM Prüβ Frontiers in Bioscience-Landmark 27 (2), 65	2022

1 - 20

计算机程序会自动估算并确定日期和引用次数。